--- license: cc-by-4.0 language: - en pretty_name: "RxGrab 2026 Brand-to-Generic Patent Cliff Audit" tags: - pharmacy - drug-pricing - generics - patent-cliff - healthcare size_categories: - n<1K --- # RxGrab 2026 Brand-to-Generic Patent Cliff Audit Aggregated cost-drop, time-to-generic, and stalled-generic audit covering 50 high-volume US prescription drugs across 24 therapeutic categories. - **License:** CC-BY 4.0 - **DOI:** [10.5281/zenodo.20632747](https://doi.org/10.5281/zenodo.20632747) - **Source study:** https://rxgrab.com/research/brand-to-generic-patent-cliff-2026/ - **Author:** Vincent Wesley Couey ([ORCID 0009-0005-6869-308X](https://orcid.org/0009-0005-6869-308X)) · published via RxGrab (rxgrab.com), part of the Lattice research network. ## What's in it Files: `data.json`. Main table `stalledGenerics` (7 rows): `brand`, `generic`, `category`, `firstGenericYear`, `twelveMonthRetainedPct`, `stallDriver`. ## Method Aggregates computed from RxGrab drug-database.json cross-referenced against FDA Orange Book, Drugs@FDA, CMS NADAC public files, GAO and ASPE drug pricing reports, IQVIA Use of Medicines public data, GoodRx public coupon-low prices, and Mark Cuban Cost Plus Drugs catalog. Price-drop percentage compares pre-generic brand cash price to post-generic median cash price 24 months after first ANDA approval. Stalled-generic flag applies where post-generic price retained 50 percent or more of pre-generic brand price for 12 or more months after first launch. Time-to-first-generic measured from FDA Orange Book composition-of-matter patent expiry (or settlement-permitted entry date) to first ANDA approval recorded in Drugs@FDA. ## Citation > Couey, V. W. (2026). *RxGrab 2026 Brand-to-Generic Patent Cliff Audit* [Data set]. RxGrab. https://doi.org/10.5281/zenodo.20632747 CC-BY 4.0 — free to use with attribution. Informational and research use only. Not medical advice; verify against the primary source and a licensed professional before relying on any value. Dated snapshot; verify current values before relying on them.